GEN Exclusives

More »

GEN News Highlights

More »
Mar 4, 2014

Arno Licenses U. Minn. Technology to Identify Likeliest Onapristone Patients

  • Arno Therapeutics said today it licensed from the University of Minnesota a cancer diagnostic technology designed to identify patients most likely to benefit from Arno's lead compound, a drug candidate now in a Phase I study.

    The technology is related to a gene expression signature derived from archived breast cancer tissue samples. The platform has potential for detecting progesterone-stimulated pathway activation and, in turn, helping find patients who would benefit from treatment with onapristone, Arno’s anti-progestin drug for men's and women's cancers.

    Under an exclusive worldwide license agreement, Arno will further develop the PR gene signature as a potentially predictive companion diagnostic for onapristone and other anti-progestins. The agreement enables the possibility of incorporating such a companion diagnostic test into ongoing and future clinical studies of onapristone.

    Onapristone is currently being evaluated in a phase I clinical trial in women who have progesterone receptor expressing tumors in France. The trial – which enrolled its first patient in January – is designed to determine the drug’s overall safety profile and identify a recommended dose for new Phase II studies. The oral, anti-progestin hormone blocker has been shown in previous Phase II clinical trials to exhibit anti-tumor activity in patients with breast cancer.

    In pre-clinical testing, onapristone has been shown to block activation of the progesterone receptor (PR), believed to inhibit the growth of APR-driven breast, endometrial and other tumors. Tests for the activated form of the progesterone receptor or APR could function as a biomarker of anti-progestin activity, as detected by a companion diagnostic under development.

    “We believe this license agreement will enable Arno's diagnostic strategy to identify and develop multiple analytical methods to identify those patients whose tumors are APR-positive and may therefore benefit from targeted onapristone therapy," David M. Jackson, vp, diagnostics for Arno, said in a statement.

    Originally developed by Schering, onapristone showed promising anti-tumor activity, as well as transient elevated liver function in earlier clinical studies in Europe on post-menopausal women with breast cancer. Arno began developing the drug in 2012 under license from Invivis Pharmaceutical, and aims to develop onapristone for a variety of tumors, including breast and endometrial cancer.

    “The potential development of a companion diagnostic for Arno's lead compound from this technology represents a significant step forward in our ability to truly realize the potential of personalized medicine," added Carol Lange, Ph.D., professor of medicine at University of Minnesota.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?